Fig. 1

MAD2L2 is highly expressed in gliomas. A The transcription levels of MAD2L2 in 24 types of cancer tissues and their corresponding normal tissues. B The expression levels of MAD2L2 in glioma and normal brain tissue. C CPTAC shows that the protein quantification levels of MAD2L2 in GBM tissue are higher than that in normal brain tissue. D The Human Protein Atlas shows that the staining intensity of MAD2L2 in GBM is higher than that in LGG and normal tissues. E The differences in MAD2L2 expression status across different WHO grades. F The immunohistochemistry results of GBM and LGG from our own cohort. G The effectiveness of MAD2L2 in distinguishing between GBM and LGG. H The perturbation score derived from DepMap indicates that MAD2L2 knockdown generally inhibits cancer cell growth across 28 different tissue-originated cancer cell lines. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001